Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons
- PMID: 12495618
- DOI: 10.1016/s0896-6273(02)01125-x
Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons
Abstract
One hypothesis for the etiology of Parkinson's disease (PD) is that subsets of neurons are vulnerable to a failure in proteasome-mediated protein turnover. Here we show that overexpression of mutant alpha-synuclein increases sensitivity to proteasome inhibitors by decreasing proteasome function. Overexpression of parkin decreases sensitivity to proteasome inhibitors in a manner dependent on parkin's ubiquitin-protein E3 ligase activity, and antisense knockdown of parkin increases sensitivity to proteasome inhibitors. Mutant alpha-synuclein also causes selective toxicity to catecholaminergic neurons in primary midbrain cultures, an effect that can be mimicked by the application of proteasome inhibitors. Parkin is capable of rescuing the toxic effects of mutant alpha-synuclein or proteasome inhibition in these cells. Therefore, parkin and alpha-synuclein are linked by common effects on a pathway associated with selective cell death in catecholaminergic neurons.
Similar articles
-
[Parkinson's disease: what have we learned from the genes responsible for familial forms?].Med Sci (Paris). 2003 May;19(5):613-9. doi: 10.1051/medsci/2003195613. Med Sci (Paris). 2003. PMID: 12836396 Review. French.
-
Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis.Hum Mol Genet. 2001 Apr 15;10(9):919-26. doi: 10.1093/hmg/10.9.919. Hum Mol Genet. 2001. PMID: 11309365
-
[Parkin, alpha-synuclein and other molecular aspects of Parkinson's disease].J Soc Biol. 2002;196(1):95-10. J Soc Biol. 2002. PMID: 12134640 Review. French.
-
Are ubiquitination pathways central to Parkinson's disease?Cell. 2003 Jul 11;114(1):1-8. doi: 10.1016/s0092-8674(03)00509-9. Cell. 2003. PMID: 12859888 Review.
-
Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.Science. 2001 Jul 13;293(5528):263-9. doi: 10.1126/science.1060627. Epub 2001 Jun 28. Science. 2001. PMID: 11431533
Cited by
-
Protein degradation pathways in Parkinson's disease: curse or blessing.Acta Neuropathol. 2012 Aug;124(2):153-72. doi: 10.1007/s00401-012-1004-6. Epub 2012 Jun 29. Acta Neuropathol. 2012. PMID: 22744791 Free PMC article. Review.
-
The Aryl Hydrocarbon Receptor: A Mediator and Potential Therapeutic Target for Ocular and Non-Ocular Neurodegenerative Diseases.Int J Mol Sci. 2020 Sep 16;21(18):6777. doi: 10.3390/ijms21186777. Int J Mol Sci. 2020. PMID: 32947781 Free PMC article. Review.
-
Understanding and treating neurodegeneration: insights from the flies.Age (Dordr). 2005 Sep;27(3):225-39. doi: 10.1007/s11357-005-2917-y. Epub 2005 Dec 31. Age (Dordr). 2005. PMID: 23598655 Free PMC article.
-
α-Synuclein and protein degradation systems: a reciprocal relationship.Mol Neurobiol. 2013 Apr;47(2):537-51. doi: 10.1007/s12035-012-8341-2. Epub 2012 Sep 2. Mol Neurobiol. 2013. PMID: 22941029 Review.
-
Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.J Neurosci. 2006 Apr 5;26(14):3685-96. doi: 10.1523/JNEUROSCI.0414-06.2006. J Neurosci. 2006. PMID: 16597723 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
